BRISTOL MYERS SQUIBB

CytomX reduces workforce to under 75, focusing on clinical-stage programs. Job postings dipped in December but expected to rise in January. BMO Capital Markets sees limited impact from Tryngolza's approval, focusing on olezarsen. Layoffs slow but major firms plan cuts in 2024. Tenaya's shares drop due to lower RNA expression in trials. STRIDES discontinuation marks a setback in obesity treatment. Protara and CG Oncology advance innovative cancer therapies. Viracta Therapeutics faces layoffs, leaving about 18 employees.

The global Sickle Cell Disease (SCD) treatment market is expected to grow to US$ 17.7 billion by 2034, driven by genetic therapy advancements and increased prevalence in regions like sub-Saharan Africa and Asia. Key players like Bluebird Bio and Novartis are innovating treatments, with a focus on gene-editing and therapies targeting the disease's root causes. Regulatory support and rising public awareness are also fueling market growth.

The report provides an in-depth analysis of the Glioblastoma market, including epidemiology, treatment practices, emerging drugs, and market trends from 2020 to 2034. It highlights the growth driven by increasing patient population and new therapies, with key companies like Bayer and Merck leading in research. Promising therapies and FDA Fast Track designations, such as LP-184, aim to address unmet medical needs in this aggressive brain cancer.

Sanofi's Sarclisa showed improved MRD negativity rates in multiple myeloma patients when added to KRd regimen, as per IsKia trial data. Despite lagging behind Darzalex in sales, new trial results could boost Sarclisa's market position. Sarclisa is also under phase 3 trial for a new combination therapy.

Cytokinetics halts ALS trial for resedemtiv after phase 3 COURAGE-ALS shows no benefit over placebo. Following FDA rejection of heart failure drug omecamtiv mecarbil, focus shifts to aficamten for HCM, with phase 3 SEQUOIA-HCM results awaited. Aficamten faces competition from BMS's Camzyos in the HCM market.

Bristol-Myers Squibb’s Opdivo and Yervoy combo shows 79% reduced risk of disease progression or death in MSI-H/dMMR metastatic CRC patients, outperforming chemotherapy. With 72% progression-free survival at two years vs. 14% for chemo, it's poised for first-line approval, challenging Keytruda.

The FDA approved subcutaneous Opdivo Qvantig for most solid tumor indications, offering a faster delivery method. Based on the CheckMate-67T trial, it showed noninferiority to intravenous Opdivo and a higher overall response rate. Approval was granted to Bristol Myers Squibb.

Novartis partners with BeiGene, paying $300M upfront for an option on ociperlimab, a TIGIT antibody in phase 3 for NSCLC, potentially adding $700M. This move aims to enhance cancer immunotherapy efficacy by combining TIGIT and PD-1/PD-L1 inhibitors, following Novartis' previous $650M deal for tislelizumab. The deal includes rights in multiple regions, with BeiGene retaining exclusivity in China and other Asian markets. TIGIT-targeting drugs are highly sought after, with various pharma companies investing heavily in their development.

The global Sickle Cell Disease (SCD) treatment market is projected to grow significantly, reaching US$ 17.7 billion by 2034, driven by genetic-based therapies and increased prevalence in regions like sub-Saharan Africa and Asia. Breakthroughs in gene-editing and medical research are fueling demand for innovative treatments, with key players like Bluebird Bio and Novartis leading advancements. Regulatory support and rising public awareness are also contributing to market expansion.

GSK's Blenrep showed a 42% reduced risk of death in multiple myeloma, outperforming Darzalex in the DREAMM-7 trial. With a 74% OS rate for BVd vs. 60% for DVd, and significant MRD negativity, it may redefine treatment for relapsed/refractory multiple myeloma. GSK aims for Blenrep's comeback, despite competition from newer therapies.